Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function
2011

Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function

publication Evidence: high

Author Information

Author(s): Chinmay S. Marathe, Christopher K. Rayner, Karen L. Jones, Michael Horowitz

Primary Institution: University of Adelaide

Hypothesis

GLP-1 and incretin-based therapies have significant effects on gastrointestinal motility.

Conclusion

GLP-1 slows gastric emptying and has important implications for glycemic control in diabetes.

Supporting Evidence

  • GLP-1 is secreted in response to food and helps regulate insulin.
  • GLP-1 slows gastric emptying, which can help lower blood sugar levels after meals.
  • Exenatide and liraglutide are GLP-1 analogues used in diabetes treatment.

Takeaway

GLP-1 is a hormone that helps control blood sugar by slowing down how fast food leaves the stomach, which can help people with diabetes.

Methodology

This review summarizes current knowledge of GLP-1's effects on gut motility at different concentrations and the motor actions of incretin-based therapies.

Limitations

The review does not cover the inhibitory action of GLP-1 on gastric acid secretion.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1155/2011/279530

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication